{"id":667002,"date":"2023-09-08T21:50:02","date_gmt":"2023-09-08T21:50:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667002"},"modified":"2023-09-08T21:50:02","modified_gmt":"2023-09-08T21:50:02","slug":"glycated-albumin-assay-market-worth-03-billion-by-2028","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/glycated-albumin-assay-market-worth-03-billion-by-2028_667002.html","title":{"rendered":"Glycated Albumin Assay Market worth $0.3 billion by 2028"},"content":{"rendered":"
\n
\"Glycated<\/a><\/div>\n
\n
The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China).<\/div>\n<\/div>\n<\/div>\n
Glycated Albumin Assay Market in terms of revenue was estimated to be worth $0.2 billion in 2023 and is poised to reach $0.3 billion by 2028, growing at a CAGR of 8.9% from 2023 to 2028 according to a new report by MarketsandMarkets\u2122<\/div>\n

Glycated Albumin Assay Market<\/a><\/strong> in terms of revenue was estimated to be worth $0.2 billion in 2023 and is poised to reach $0.3 billion by 2028, growing at a CAGR of 8.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Government assistance is stimulating the market. Players in the glycated albumin assay market have significant potential in developing nations like India and Japan.<\/p>\n

Additionally, the aging population in developed and developing nations would favorably impact the market for glycated albumin assay. The prevalence of age-related illnesses like diabetes and pancreatic disorders is anticipated to rise dramatically as the senior population is forecast to grow quickly. Numerous test prescriptions to assess the levels of creatinine, albumin, glucose, ketones, and bilirubin are caused by diagnosing and treating such disorders, which is driving the market’s expansion. Browse through 100 market data tables and 44 figures spread across 180 pages and the in-depth TOC of the glycated albumin assay market.<\/p>\n

Download an Illustrative overview: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=265553363<\/a><\/strong><\/p>\n

The type 2 diabetes segment accounted for the largest share of the glycated albumin assay market, by application segment, in 2022<\/strong><\/p>\n

Based on application, the glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. The type 2 diabetes segment accounted for the largest share of the glycated albumin assay market, mainly due to increased focus on type 2 diabetes care and increased funding for diagnostic research.<\/p>\n

Hospitals and diabetes care centers segment to register the highest growth rate during the forecast period<\/strong><\/p>\n

The significant market share of this sector is mostly due to an increased emphasis on early disease diagnosis. Additionally, hospitals and diabetes care facilities are committed to providing patients with diabetes-specialized care. Their focus on comprehensive diabetes care makes them primary locations for conducting glycated albumin assays, which are important diagnostic tests for monitoring glycemic control.<\/p>\n

North America is the largest regional market during the forecast period<\/strong><\/p>\n

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the five main geographic segments of the worldwide glycated albumin assay market. In 2022, the glycated albumin assay market’s largest regional market was North America. The government’s support for regional research and increased funding for the creation of preventive care diagnostics can be used to explain North America’s significant market dominance.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=265553363<\/a><\/strong><\/p>\n

Glycated Albumin Assay Market Dynamics:<\/strong><\/p>\n

Drivers:<\/strong><\/p>\n

    \n
  1. Rising prevalence of diabetes<\/li>\n<\/ol>\n

    Restraints:<\/strong><\/p>\n

      \n
    1. Unfavorable reimbursement scenario<\/li>\n<\/ol>\n

      Opportunities:<\/strong><\/p>\n

        \n
      1. Rising investments in healthcare and life sciences research<\/li>\n<\/ol>\n

        Challenges:<\/strong><\/p>\n

          \n
        1. Changing regulatory landscape<\/li>\n<\/ol>\n

          Key Market Players:<\/strong><\/p>\n

          The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China).<\/p>\n

          Get 10% Free Customization on this Report: https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=265553363<\/a><\/strong><\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           MarketsandMarkets\u2122 Research Private Ltd.<\/a>
          Contact Person:<\/strong> Mr. Aashish Mehra
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 18886006441
          Address:<\/strong>630 Dundee Road Suite 430
          City:<\/strong> Northbrook
          State:<\/strong> IL 60062
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.marketsandmarkets.com\/Market-Reports\/glycated-albumin-assay-market-265553363.html<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China). Glycated Albumin Assay Market in terms of revenue was … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-667002","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=667002"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667002\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=667002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=667002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=667002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}